NFG
SABS icon

Nadler Financial Group’s SAB Biotherapeutics SABS Stock Holding History

Nadler Financial Group’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,375
Closed -$9.45K – 119
2023
Q4 		$9.45K Hold
1,375
– – ﹤0.01% 106
2023
Q3 		$8.66K Hold
1,375
– – ﹤0.01% 108
2023
Q2 		$11.4K Hold
1,375
– – ﹤0.01% 116
2023
Q1 		$6.05K Hold
1,375
– – ﹤0.01% 114
2022
Q4 		$8.11K Buy
+1,375
New +$12.6K ﹤0.01% 110
2022
Q1 		– Sell
-1,100
Closed -$86K – 135
2021
Q4 		$86K Buy
+1,100
New +$103K 0.01% 132

Other funds holding SABS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Nadler Financial Group's SABS Position: Q1 2024 in Review

Nadler Financial Group sold out of SAB Biotherapeutics (SABS) in Q1 2024, closing a stake of 1,375 shares — an estimated $9.45K sold.

Nadler Financial Group first reported a position in SABS in Q4 2021 and held it in 6 quarters. The position peaked at $86K in Q4 2021. 24 funds tracked by Wall St. Rank hold SABS as of Q1 2024.

  • Nadler Financial Group reported no remaining SAB Biotherapeutics position as of Q1 2024 after selling out during the quarter.
  • Nadler Financial Group sold 1,375 SAB Biotherapeutics shares in Q1 2024, an estimated $9.45K.
  • Nadler Financial Group first reported a position in SAB Biotherapeutics in Q4 2021 and held it in 6 quarters.
  • Nadler Financial Group's SAB Biotherapeutics position peaked at $86K in Q4 2021.
  • 24 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2024.

Based on Nadler Financial Group's 13F filing for Q1 2024, filed 26 Apr 2024.